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Fetal growth restriction is a syndrome that is marked by failure
of the fetus to reach its growth potential with consequences that
are related to the underlying disorder as well as the severity of fetal
disease. Because a small for gestational age (SGA) fetus may be the
consequence of many underlying etiologies, the differential diag-
nosis always includes maternal disease, placental insufﬁciency,
aneuploidy, nonaneuploid syndromes, and viral infection.
Intrauterine growth retardation/restriction (IUGR) pregnancies
had more antepartum and intrapartum complications, including
antepartum steroid treatment, premature delivery, and cesarean
delivery. In addition, neonates in the IUGR group were more likely
to have 1- and 5-minute Apgar scores < 5 and more often were
admitted to the neonatal intensive care unit. More IUGR pregnan-
cies ended in intrauterine fetal death, although the difference
was not statistically signiﬁcant. Signiﬁcantly more IUGR infants
died while hospitalized (4.5% vs. 0.5%).
Deﬁnitions
From the 1960s, growth has been classiﬁed by the absolute birth
weight value as low birth weight (LBW < 2500 g), very low birth
weight (< 1500 g), extremely LBW (< 1000 g), or macrosomia (>
4000 g). In the 1970s, growth was classiﬁed by the birth-weight
percentile, and this resulted in the currently accepted classiﬁcation
of birth weight as very SGA (< 3rd percentile), SGA (< 10th percen-
tile), appropriate for gestational age (AGA, 10the90th percentile), or
large for gestational age (> 90th percentile). Although birth-weight
percentiles are superior in identifying the small neonate, they fail to
account for proportionality of growth and the growth potential of
the individual. Therefore, neonates that have a normal birth-
weight percentile but abnormal body proportion as a result of
differential growth delay may be missed. Similarly, birth-weight
percentiles do not distinguish between the small neonate who is
normally grown given his or her genetic potential, and the neonate
who is growth restricted because of a disease process.
The ponderal index {[birth weight (g)/crown-to-heel
length]  100} has a high accuracy for the identiﬁcation of IUGR
and macrosomia. This index correlates more closely with perinatal
morbidity and mortality than traditional birth-weight percentiles
but may miss the proportionally small and lean, IUGR neonate.
Classiﬁcation
Accordingly, parameters of head, abdominal, and skeletal growth
are related to population-based reference ranges. In addition to the
detection of smaller individual measurements and lower weight,http://dx.doi.org/10.1016/j.tjog.2014.01.003
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asymmetric and symmetric. In the asymmetric growth pattern, the
abdominal circumference (AC) and lower body shows a signiﬁcant
growth delay, whereas there is relative or absolute sparing of head
growth. In the symmetric form, body and head growth are similarly
affected. Asymmetric growth patterns result from two processes.
First, liver volume is reduced because of depletion of glycogen stores
as the result of limited nutrient supply, which leads to a decrease in
AC. Second, elevations in placental blood ﬂow resistance increase
right cardiacafterloadandpromotediversionof the cardiacoutput to-
ward the left ventricle because of the parallel arrangement of the fetal
circulation and the presence of central shunts. Blood and nutrient
supply to the upper part of the body thus increase, presumably result-
ing in relative head sparing. Symmetrically restricted fetal growth
typically results when interference with the growth process results
in decreased cell numbers and cell size, typically resulting from a
ﬁrst-trimester insult. As a result, all parts of the body are equally
affected, producing uniformly small growth. Uteroplacental insufﬁ-
ciency is typically associated with asymmetric fetal growth delay
because of the aforementioned mechanisms.
Aneuploidy, nonaneuploid syndromes, and viral infections
disrupt either the regulation of growth processes or interfere
with growth at the stage of cell hyperplasia. This problem typically
results in a symmetric growth delay. Speciﬁc conditions, such as
skeletal dysplasia, may produce distinct growth patterns by their
differential effects on axial and peripheral skeletal growth. Because
growth is dynamic, the pattern of IUGR may evolve in the course of
gestation. Placental disease may initially present with relative head
sparing but eventually progresses to symmetric growth delay as
placental insufﬁciency worsens. Alternatively, the acute course of
a fetal viral illness may temporarily result in arrested growth
with subsequent resumption of a normal growth pattern.
Small fetal or neonatal size have to be considered as a physical
sign rather than a speciﬁc disease warranting further investigation
of underlying causes. SGA refers to neonates in whom no causative
pathology for the small size is evident. From the perspective of the
managing perinatologist, prenatal identiﬁcation of IUGR is most
relevant because it allows appropriate prospective fetal manage-
ment. To formulate a uniform approach to prenatal detection and
perinatal management, an understanding of the maternal and fetal
effect of placental insufﬁciency is essential.
Etiologies
Maternal causes of IUGR include vascular disease such as hyper-
tensive disorders of pregnancy, diabetic vasculopathy, chronic renal
disease, collagen vascular disease, and thrombophilia. The associ-
ated decrease in uteroplacental blood ﬂow is responsible for theby Elsevier Taiwan LLC. All rights reserved.
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ume expansion, as may be observed in hypertensive disorders or
genetic conditions such as angiotensinogen gene mutations, or
living at high altitude have also been reported to compromise
placental blood ﬂow by reducing the circulating blood volume,
hyperviscosity, and sludging. In addition, reduction of maternal
oxygenation found in women living at high altitude, or with
cyanotic heart disease, parenchymal lung disease, or reduced oxy-
gen carrying capacity, as observed with certain hemoglobinopa-
thies and anemias, may be responsible for the cases of IUGR
described in these conditions.
Poor maternal weight gain is a long-recognized risk factor for
IUGR. Studies of the offspring of pregnant women with dietary re-
strictions suggest that limited protein intake, especially prior to
26 weeks' gestation, can result in symmetric IUGR, whereas caloric
restriction (maternal intake of 600e900 calories daily for 6months)
has only moderate effects on birth weight. Nevertheless, maternal
prepregnancy weight and weight gain in pregnancy are two of
the most important variables contributing to birth weight. It is
conceivable that malnutrition caused by gastrointestinal syn-
dromes such as Crohn's disease, ulcerative colitis, or bypass surgery
can result in lower birth weight. However, an associationwith IUGR
is infrequent in these conditions.
Glucose is a critical fetal nutrient driving longitudinal fetal
growth. Reduced glucose supply to the fetoplacental unit can result
in IUGR. This was suspected by Economides and Nicolaides [1], who
observed signiﬁcantly lower maternal and fetal glucose levels in
IUGR fetuses. Khouzami et al [2] documented a signiﬁcant associa-
tion between relative maternal hypoglycemia on a 3-hour oral
glucose tolerance test and subsequent birth of non-LBW, but
growth-restricted babies. Sokol et al [3] and Langer et al [4] have
conﬁrmed that a ﬂat maternal response to glucose loading
increased the risk for poor fetal growth as much as 20-fold.
Maternal drug ingestion may result in IUGR by a direct effect on
fetal growth as well as through inadequate dietary intake. Smoking
produces a symmetrically smaller fetus through reduced uterine
blood ﬂow and impaired fetal oxygenation, and is a major cause
of IUGR in developed countries. The consumption of alcohol and
the use of warfarin or hydantoin derivatives are now well known
to produce particular dysmorphic features in association with
impaired fetal growth. Mills et al [5] have demonstrated a signiﬁ-
cant increase in the risk of IUGR with the consumption of one to
two drinks daily, in the absence of fetal alcohol syndrome. Maternal
use of cocaine has been associated with not only IUGR but also
reduced head circumference (HC) growth.
Berkowitz et al [6] found no evidence that the ﬁrst births of
women aged between 30 years and 34 years or those > 35 years
were at increased risk for IUGR. Chronic medical conditions of the
mother do increase the risk of IUGR. However, if underlying medi-
cal complications are controlled for, maternal age is not related to
restricted fetal growth. Multiple risk factors can act synergistically
on fetal growth. For example, the adverse effect of smoking is
doubled in thin white women and further potentiated by poor
maternal weight gain [7].
Fetoplacental causes can result in IUGR due to abnormalities of
the fetus or placenta, or both. Chromosomal abnormalities, congen-
ital malformations and genetic syndromes have been associated
with < 10% of cases of IUGR. Similarly, intrauterine infection,
although long recognized as a cause of IUGR, also accounts for <
10% of all cases. However, genetic and infectious etiologies are of
special importance because perinatal and long-term outcome are
ultimately determined by the underlying condition with little po-
tential effect through perinatal interventions.
IUGR has been observed in 53% of cases of trisomy 13, and 64% of
cases of trisomy 18, and may be manifest as early as the ﬁrsttrimester [8]. Other conditions that may present with IUGR include
skeletal dysplasia and Cornelia de Lange syndrome. The online
database of inheritance in humans lists > 100 genetic syndromes
that may be associated with IUGR. Of the infectious agents, herpes,
cytomegalovirus, rubella, and Toxoplasma gondii are well-
documented causes of symmetric IUGR.
Abnormal placental development with subsequent placental
insufﬁciency is a relatively common problem affecting about one
third of patients with IUGR or about 3% of all pregnancies. Placental
insufﬁciencyaccounts for themajority of IUGR in singletonpregnan-
cies [8e10]. An absolute or relative decrease in placental mass af-
fects the quantity of substrate the fetus receives and antedates the
development of IUGR. Thus, abnormal placental vascular develop-
ment, circumvallate placenta, partial placental abruption, placenta
accreta, placental infarction, or hemangioma may result in IUGR.
Intrinsic placental pathology such as a single umbilical artery and
placental mosaicism has been identiﬁed in some cases of IUGR.
Placental implantation in the loweruterine segment inplacenta pre-
via is considered suboptimal for nutrient exchange and, therefore,
may result in IUGR even in the absence of chronic hemorrhage.
Twin gestation is often associated with IUGR. Gruenwald [11]
observed that the growth curve of twins deviated from that of sin-
gletons, with a progressive fall of growth after 32 weeks. Thus,
twins and higher order multiples represent a group of fetuses at
high risk for IUGR, as conﬁrmed by an incidence of 17.5% in one
study.
Placentas from 50 full-term, uncomplicated deliveries were
collected; 28 of them were associated with IUGR babies and 22
were from normal-weight babies. Placental weights and volumes
weremeasured. Pieces of placental tissueswere formalin-ﬁxed, pro-
cessed, and embedded in parafﬁn. Seven-micron sections were cut
and stained with hematoxylin and eosin stain. Histomorphometric
and stereological studies were performed. IUGR placental weights
and volumeswere lower than those of controls. Surface areas of villi
of IUGR placentas had a mean of 8.19 m2 [standard deviation
(SD) ± 2.88]. For control placentas, the mean was 10.02 m2
(SD ± 1.83). The mean value of the surface area of villi of the IUGR
group was signiﬁcantly lower than that of the control group. These
ﬁndings pointed to a defect in the normal interaction between
trophoblast and maternal tissue, leading to a reduced surface area
of villi. Because the surface area of the villi presents the interface be-
tween maternal and fetal circulation, its reduction might be the
cause of idiopathic intrauterine growth restriction [12].
Another study examined the relationship of cigarette smoking
and endothelial function in pregnant women by comparing
smokers with nonsmokers. Endothelial function was assessed at
28e32 weeks of gestation by ﬂow-mediated dilatation (FMD) using
ultrasound of the brachial artery. The initial FMD was signiﬁcantly
different between the smoking group (n ¼ 21) at 4.0 ± 2.3, indi-
cating endothelial dysfunction, and the nonsmoking group
(n ¼ 20) at 9.7 ± 4.0 (p < 0.001). After smoking, this difference in
the groups persisted. Babies who were growth restricted (< 10th
percentile) had mothers with a signiﬁcantly lower FMD, that is
endothelial dysfunction. This work demonstrates persistent endo-
thelial dysfunction in smoking pregnant women [13].
The site of the placenta within the uterus is likely to be an
important factor in placental blood ﬂow and consequently in
the outcome of pregnancy. Placental location has been implicated
in preterm birth, fetal malposition and malpresentation, and the
risk of preeclampsia, but its association with fetal growth is not
clear. A retrospective caseecontrol study examined the relation-
ship between placental location at midtrimester and IUGR,
deﬁned as a sonographically estimated fetal weight below the
10th percentile for gestational age using population-speciﬁc fetal
growth curves. Participants were 67 women with well-dated
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nography was carried out at 16e20 weeks' gestation, and the
relationship between IUGR and placental site was determined
by multivariable logistic regression analysis. Black mothers
made up a higher proportion of IUGR cases, but there were no
group differences in maternal age, gravidity, parity, body mass in-
dex, or gestational age at the time of the study. Anterior and pos-
terior placental sites were most frequent in both IUGR cases and
non-IUGR controls. After adjusting for potential confounding fac-
tors (including race, chronic hypertension, and hypertensive dis-
orders of pregnancy), IUGR pregnancies were almost fourfold
more likely to have lateral rather than anterior or posterior
placentation. The odds ratio was 3.8, with a 95% conﬁdence inter-
val of 1.3e11.2. Mean birth weight was about 2 kg lower in the
IUGR cases than in non-IUGR control pregnancies. These ﬁndings,
along with nonuniform distribution of blood ﬂow to the uterus,
suggest that placental location may be a major determinant of
placental blood ﬂow [14].
Fetal biometry
Ultrasound criteria have emerged as the diagnostic standard
used in the identiﬁcation of IUGR. For this purpose, sonographic
measurements of fetal bony and soft structures are related to refer-
ence ranges for gestation. Two patterns of altered head growth
were described: In “late ﬂattening” (Type 1, asymmetric type),
the biparietal diameter (BPD) increases normally until late preg-
nancy and then lags behind. In the “low-proﬁle” or symmetric
type, impaired head growth occurs much earlier in gestation
(Type 2). The asymmetric type represents approximately two thirds
of cases of IUGR. The fetal AC is related to hepatic glycogen storage
and liver size, therefore correlating closely with the nutritional
state. Campbell [15] and Wilkin [16] were the ﬁrst to relate com-
bined measurements of the BPD and AC to birth weight. Additional
direct measurements that are primarily used in clinical practice
today include the HC and femur length (FL). Secondary direct mea-
surements include the transverse cerebellar diameter and the hu-
merus length (HL). The most important calculated ultrasound
variable of fetal growth is the sonographically estimated fetal
weight (SEFW). Numerous investigators have identiﬁed distinct
fetal ultrasound parameters that are useful in the calculation of
the SEFW. All of the techniques incorporate an index of abdominal
size as a variable contributing to the estimation of fetal weight.
Population-speciﬁc formulas have been derived to generate refer-
ence limits that generally have 95% conﬁdence limits deviating
approximately 15% from the actual value.
Accurate estimation of fetal growth from these fetal measure-
ments requires knowledge of the gestational age as a reference
point to calculate percentile ranks. An estimated date of conﬁne-
ment should be based on the last menstrual period when the sono-
graphic estimate of gestational age is within the predictive error
(5 days in the 1st trimester, 10 days in the 2nd trimester, and
21 days in the 3rd trimester). When the estimated date of conﬁne-
ment is set by this method or a ﬁrst-trimester ultrasound, it should
not be changed because such practice interferes with the ability to
diagnose IUGR.
Measurement of the BPD alone is a poor tool for the detection of
IUGR. The physiologic variation in size inherent with advancing
gestation is high. Most IUGR fetuses presenting with asymmetric
growth restriction and delayed ﬂattening of the cranial growth
curve would be detected relatively late. Factors that interfere
with a technically adequate measurement of the BPD include alter-
ations of the cranial shape by external forces (e.g., oligohydramnios,
breech presentation) and direct anteroposterior position of the
fetal head.The HC is not subject to the same extrinsic variability as the BPD.
The measurement technique is important because calculated HC
measurements are systematically smaller than those directly
measured. Thus, the nomogram selected should be based on mea-
surements obtained using the same methodology. As a screening
tool for IUGR, the HC poses a similar problem because the BPD in
that two thirds of IUGR fetuses with asymmetric growth pattern
would be detected late.
The transcerebellar diameter is one of the few soft-tissue mea-
surements that correlate well with gestational age, being relatively
spared from the effects of mild tomoderate uteroplacental dysfunc-
tion. Whether its measurement offers any advantage over bony
measurements in the assessment of compromised fetal growth is
controversial.
The AC is the single best measurement for the detection of IUGR
[14]. The most accurate AC is the smallest directly measured
circumference obtained in a perpendicular plane of the upper
abdomen at the level of the hepatic vein between fetal respirations.
The AC percentile has both the highest sensitivity and negative pre-
dictive value for the sonographic diagnosis of IUGR whether
deﬁned postnatally by birth-weight percentile or ponderal index.
Using the 10th percentiles as cutoffs, the AC has a higher sensitivity
(98% vs. 85%) but lower positive predictive value than the SEFW
(36% vs. 51%). Its sensitivity is further enhanced by serial measure-
ments at least 14 days apart. Because of its high sensitivity, some
type of abdominal measurement should be part of every sono-
graphic growth evaluation. But because the AC reﬂects fetal nutri-
tion, it should be excluded from the calculation of the composite
gestational age after the early second trimester.
Calculation of the ratio between the HC and AC (HC/AC ratio) has
been proposed as a tool to increase detection of the fetus with
asymmetric growth restriction [17,18]. In the normally growing
fetus, the HC/AC ratio exceeds 1.0 prior to 32 weeks' gestation, is
approximately 1.0 at 32e34weeks' gestation, and falls below 1.0 af-
ter 34 weeks' gestation. In fetuses with asymmetric growth restric-
tion, the HC remains larger than that of the body, resulting in an
elevated HC/AC ratio, whereas the ratio remains normal in symmet-
ric IUGR in which both direct measurements are equally affected.
Using the HC/AC ratio, 70e85% of IUGR fetuses are detected, with
a reduction in false-negative diagnoses. Thus, a single set of mea-
surements, even when determined in the latter part of pregnancy,
can be very helpful in evaluating the status of intrauterine growth.
As noted earlier, the SEFW has a lower sensitivity but higher
positive predictive value than the AC and does not add to the AC
percentile for the diagnosis of IUGR. However, an SEFW below
the 10th percentile provides a graphic image easy for both patient
and referring physician to conceptualize. Therefore, use of the esti-
mated fetal weight has become themost commonmethod for char-
acterizing fetal size and thereby growth abnormalities [19].
Fetal body composition
Several studies have examined fetal subcutaneous fat content
using ultrasound examination. Subcutaneous fat deposition has
been examined in the face, abdomen, arm, and thigh [17e20].
Reduction in facial fat stores has been strongly associated with be-
ing SGA. Using ultrasound, Padoan et al [21] showed that both sub-
cutaneous mass (fat mass) and lean mass (bone and muscle mass)
are reduced in growth-restricted fetuses but that proportionately
the subcutaneous mass is reduced to a greater extent than lean
mass. This reduction in fat content is consistent with observations
made in the growth-restricted neonate and may prove to be a sen-
sitive indicator of the small fetus at increased risk for perinatal
complications. The optimal method of in utero assessment of fetal
fat has not yet been determined. However, other authors have
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15th percentile with an odds ratio of 1.9 for mortality in newborns
with birth weights between the 10th percentile and 15th percentile
[22].
The weights of preterm infants are not normally distributed as
they are at term, producing a signiﬁcant discrepancy between birth
weight-deﬁned growth curves and SEFW-deﬁned growth curves in
preterm gestation [23]. SEFWgrowth curves are generated from pa-
tient samples representing the entire obstetric population at any
gestational age. By contrast, preterm live birth normative data ta-
bles reﬂect only those individuals who have delivered under
abnormal circumstances. Thus, the SEFW consistently demonstrate
higher fetal weights over the range of preterm gestation than do
birth weight-generated growth curves. Therefore, use of a SEFW
cutoff below the 10th percentile is more appropriate to deﬁne
abnormal fetal growth as the ability to identify fetuses at increased
perinatal risk is enhanced [24].Fetal anatomic survey
Although the sonographic survey of fetal anatomy does not pro-
vide an assessmentof fetal growth, it is theﬁrst step toward the inves-
tigation of an underlying etiology. The anatomic survey should focus
on the detection ofmarkers of aneuploidy, nonaneuploid syndromes,
and fetal infection, as well as any anatomic defects. The relationship
between aneuploidy and fetal anomalies such as gastroschisis,
omphalocele, diaphragmatic hernia, congenital heart defects, and
sonographic markers such as echogenic bowel, nuchal thickening,
and abnormal hand positioning. Abnormalities of skull contour,
thoracic shape, or disproportional shortening of the long bones may
be indications of skeletal dysplasia or thanatophoric dwarﬁsm.Amniotic ﬂuid assessment
The regulation of amniotic ﬂuid volume (AFV) by the late second
and third trimester is primarily dependent on fetal urine output,
production of pulmonary ﬂuid, and fetal swallowing. Placental
dysfunction and fetal hypoxemia both may result in decreased
perfusion of the fetal kidneys with subsequent oliguria and
decreasing AFV. Although the accuracy of ultrasound in the assess-
ment of actual AFV is poor, two techniques are used that can pro-
vide important diagnostic and prognostic information [25].
Overall, estimation of AFV in itself is a poor screening method
for IUGR or fetal academia [26]. However, in clinical practice, it is
an important diagnostic and prognostic tool. Oligohydramnios
may be the ﬁrst sign of fetal growth restriction detected on ultraso-
nography preceding an assessment for lagging fetal growth. If
gestational age is known, ultrasound assessment of fetal growth
based on the HC, AC, FL, and SEFW can be performed. If gestational
age is unknown, measurements of the FL/AC ratio and single amni-
otic ﬂuid pocket have to be used because they are independent of
gestational age. Up to 96% of fetuses with ﬂuid pockets < 1 cm
may be growth restricted. In patients in whom growth delay is
already suspected, AFV can be an important differential diagnostic
marker. In the setting of small fetal size, abundant AFV suggests
aneuploidy or fetal infection [27], whereas normal or decreased
amniotic ﬂuid is compatible with placental insufﬁciency. The vol-
ume of amniotic ﬂuid also has prognostic signiﬁcance for the course
of labor. Groome et al [28] demonstrated that oligohydramnios
associated with fetal oliguria is associated with a higher rate of
intrapartum complications that may be attributed to reduced
placental reserve.Doppler velocimetry
Similar to the assessment of AFV, the role of Doppler velocime-
try in the management of fetal IUGR is unique because it serves as a
diagnostic as well as a monitoring tool. Doppler ﬂow velocity wave-
forms may be obtained from arterial and venous vascular beds in
the fetus. Arterial Doppler waveforms provide information on
downstream vascular resistance, which may be altered because of
structural changes in the vasculature or regulatory changes in
vascular tone. The systolic/diastolic ratio (S/D), resistance index
(RI), and the pulsatility index (PI) are the three Doppler indices
most widely used to analyze arterial blood ﬂow resistance. An in-
crease in blood ﬂow resistance manifests itself with a relative
decrease in end-diastolic velocity, resulting in an increase in all
three Doppler indices. Of these indices, the PI has the smallest mea-
surement error and narrower reference limits. With extreme in-
crease in blood ﬂow resistance, end-diastolic forward velocity
may be absent (AEDV) or reversed (REDV).
Venous Doppler parameters complement evaluation of fetal car-
diovascular status by providing an assessment of cardiac forward
function. Forward blood ﬂow in the venous system is determined
by cardiac compliance, contractility, and afterload, and it is charac-
terized by a triphasic ﬂow pattern that reﬂects pressure volume
changes in the atria throughout the cardiac cycle [29]. The descent
of the AV ring during ventricular systole and passive diastolic ven-
tricular ﬁlling generates the systolic and diastolic peaks, respec-
tively (the S- and D-wave). The sudden increase in right atrial
pressure with atrial contraction in late diastole causes a variable
amount of reverse ﬂow, producing a second trough after the D
wave (the a-wave). Themagnitude of forward ﬂow during the atrial
systole varies considerably in individual veins: reversal may be
physiologic in the inferior vena cava and hepatic veins but it is al-
ways abnormal in the ductus venosus. Multiple venous Doppler
indices have been described to characterize this complex waveform
without any clear advantages of individual indices [30].
In the diagnostic assessment of the small fetus, examination of
umbilical and middle cerebral artery Doppler studies are the
most important to evaluate for placental dysfunction as the under-
lying etiology. Randomized trials and meta-analyses conﬁrm that
the combined use of fetal biometry and umbilical artery Doppler
signiﬁcantly reduces perinatal mortality and iatrogenic interven-
tion because documentation of placental vascular insufﬁciency
effectively separates growth-restricted fetuses that require surveil-
lance and possible intervention from constitutionally small fetuses
[31,32].
A free umbilical cord loop is examined with continuous or
pulsed Doppler ultrasound far from the fetal and placental inser-
tions (e.g., midcord segment). Most current ultrasound equipment
allows concurrent use of color and pulsed Doppler with improved
reproducibility of measurements. Vascular damage affecting
approximately 30% of the placenta produces elevations in the
Doppler index. More marked abnormalities result in umbilical ar-
tery AEDV or REDV. Milder forms of placental vascular dysfunction,
especially near term, may not produce elevation of umbilical artery
blood ﬂow resistance sufﬁciently to be detectable by traditional
Doppler methods [33]. If placental gas exchange is sufﬁciently
impaired to result in perceived fetal hypoxemia, a decrease in mid-
dle cerebral artery Doppler resistance may occur. Another Doppler
index frequently used clinically to detect this condition is the ratio
between umbilical artery pulsatility as an index of vasoconstriction
in the placenta and middle cerebral artery pulsatility as an index of
vasodilation in the fetal brain. In milder forms of placental disease
with near-minimal increase in umbilical artery blood ﬂow resis-
tance, the cerebroplacental Doppler ratio (CPR) may decrease. Gra-
mellini et al [34] demonstrated that a value below 1.08 identiﬁed
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Singh et al [35] indicated that this predictive accuracy of the CPR
decreased after 34 weeks' gestation. This is presumably attributable
to an increasing number of growth-restricted fetuses that may have
normal umbilical artery blood ﬂow resistance near term but
demonstrate isolated “brain sparing” as the only sign of placental
insufﬁciency of oxygen transfer [36] and these fetuses are at risk
for adverse outcome [37,38].
Because of the variable presentation across gestation, compre-
hensive Doppler assessment of placental function should include
umbilical and middle cerebral arteries. For the umbilical artery, an
abnormal test result is deﬁned as a Doppler index measurement
of > 2 SDs above the gestational age mean and/or a loss of end-
diastolic velocity. Like growth curves, it is best to use nomograms
developed from a local or comparable population. For the CPR and
also for the middle cerebral artery, a > 2 SD decrease of the index
is considered abnormal [35,36]. In a setting of small fetal size, these
ﬁndings identify those fetuses at greatest risk for adverse outcome.
A recent study prospective observed the singletons with IUGR
(AC < 5th percentile) who underwent serial standardized umbilical
artery (UA), middle cerebral artery (MCA), ductus venosus (DV), and
umbilical vein (UV) Doppler surveillance. Time intervals between
progressive Doppler abnormalities and patterns of deterioration
were related to UA Doppler status and gestational age. Six hundred
and sixty-eight longitudinal examinations were performed in 104
fetuses, identifying three patterns of progression: (1)mild placental
dysfunction (n¼ 34) that remained conﬁned to the UA/MCA. The UA
became abnormal at a median of 32 weeks' gestation but the PI
never exceeded 3 SD above normal. Progression took a median of
33 days, requiring delivery at a median of 35 weeks; (2) progressive
placental dysfunction (n ¼ 49). Initially normal UA Doppler PI at
29 weeks' gestation increased beyond 3 SD, progressing to
abnormal MCA, absent/reversed UA diastolic ﬂow, abnormal DV,
andUVpulsations in 9-day intervals requiring delivery by33weeks;
and (3) severe early-onset placental dysfunction (n¼ 21). Markedly
elevated UA PI established by 27 weeks' gestation was associated
with rapid (7-day intervals) progression to abnormal venous
Doppler with median delivery at 30.6 weeks. Gestational age at
onset, time to delivery, and progression intervals were different be-
tween patterns (all p < 0.05). The characteristics of cardiovascular
manifestations in IUGR are determined by the gestational age at
onset and the severity of placental disease. Recognition of these fac-
tors is critical for planning fetal surveillance in IUGR [37].
Some authors showed a low combined cardiac output (CCO) to
the placenta (placenta/CCO fraction) has been reported in
growth-restricted (IUGR) fetuses, but the temporal sequence of
these modiﬁcations in relation to other changes in the fetal circula-
tion is unknown. A report of 340 singleton nulliparous pregnancies
characterized at 20e24weeks by abnormal uterine artery PI values.
At this gestational age they measured fetal biometry and Doppler
waveforms from the UA, MCA, DV, UV, and outﬂow tracts of both
ventricles. The diameters of the semilunar valves and UV were
measured and CCO (left and right cardiac outputs) and UV blood
ﬂow were calculated. The placenta/CCO fraction was calculated as
UV ﬂow as a percentage of CCO. There were 283 pregnancies
with birth weight  10th percentile and normal UA-PI throughout
gestation (Group A), 34 with birth weight < 10th percentile and
normal UA-PI throughout gestation (Group B) and 23 with birth
weight < 10th percentile and abnormal UA-PI developing later in
gestation (Group C). At 20e24 weeks there were no differences
among the three groups in fetal biometric parameters, PI values
from the UA, MCA, and DV, and CCO. UV ﬂow and placenta/CCO
fraction were signiﬁcantly lower in Group C compared with Group
A but not in Group B. In fetuses developing IUGR secondary to
placental compromise, UV ﬂow and placental/CCO fraction arealready reduced by 20e24 weeks, and that this reduction occurs
earlier than modiﬁcations in fetal size and arterial and venous PI
values [38].
Invasive testing
Several invasive tests for the evaluation of the fetus with sus-
pected IUGR have been described. From a clinical standpoint, there
are only a few studies of critical importance. These include
maternal Toxoplasmosis, Other (syphilis, varicella-zoster, parvo-
virus B19), Rubella, Cytomegalovirus (CMV), and Herpes infections
(TORCH) serology and invasive fetal testing to obtain amniotic ﬂuid
or fetal blood for karyotyping to rule out a chromosomal abnormal-
ity such as trisomy 13, 18, or 21. Trisomy 18 may present with the
unusual combination of growth restriction and polyhydramnios.
If the diagnosis of a lethal anomaly can be made with certainty, ce-
sarean delivery for fetal distress is unnecessary and may be pre-
vented. Viral polymerase chain reaction studies can be performed
if there is a clinical suspicion based on the ultrasound examination
or in the maternal history.
Evaluation of fetal erythropoietin and amino acid concentrations
are also markers for fetal compromise with prognostic effect. Eryth-
ropoietin production in the fetus, as in the adult, is stimulated by the
presenceof anemiaorhypoxia, andmaybeassociatedwith increased
red blood cell production depending on erythropoietic reserve.
Elevated blood or amniotic ﬂuid erythropoietin levels may be of
help in identifying IUGR fetuses at risk for long-term morbidity
[39]. Ruth et al [40] identiﬁed an association between cord blood
erythropoietin levels anddevelopmental outcome including cerebral
palsy and death at 2 years in offspring with evidence of acute
asphyxia at birth. None of these patients hadpreeclampsia. Neonates
from pregnancies complicated by preeclampsia had elevated cord
erythropoietin levels regardless of outcome.
An increase in the cord blood glycine/valine (GV) ratio is a spe-
ciﬁc response to intrauterine starvation resulting from reduction in
phosphoenolpyruvate carboxykinase activity, a rate-limiting
enzyme for gluconeogenesis. Elevations of the GV ratio are
observed in fetal life and have been shown to be inversely propor-
tional to fetal arterial oxygen content. However, in contrast to the
neonate in whom such an increased ratio is predictive of speciﬁc
neonatal risks including hypoglycemia and death, such a relation-
ship has not been demonstrated for elevations demonstrated in
fetal life [41]. Although fetal erythropoietin and amino acid levels
are of academic interest, they currently add little to the contempo-
rary clinical management of the IUGR fetus.
Management
A study investigated whether maternal growth hormone sup-
plementation in pregnant sheep could reverse IUGR induced by
placental embolization. The animals were randomized into control,
intrauterine growth restriction þ saline, or intrauterine growth
restriction þ growth hormone (twice daily injections of 0.1 mg/kg
growth hormone) groups. Intrauterine growth restriction was
induced by twice daily placental embolization between 93 days'
gestation and 99 days' gestation, and treatment was from
100 days' gestation to 128 days' gestation (term ¼ 147 days' gesta-
tion). Embolization reduced fetal growth rate and body weight but
increased brain-to-liver weight ratio. Growth hormone treatment
signiﬁcantly increased fetal growth rates and fat deposition, and
improved fetal body weight and length, but not liver weight.
Growth hormone treatment produced hydranencephalic brain le-
sions in some fetuses. Maternal growth hormone treatment
partially reversed intrauterine growth restriction caused by
placental insufﬁciency. However, the possible connection between
Correspondence / Taiwanese Journal of Obstetrics & Gynecology 53 (2014) 435e440440growth hormone treatment and fetal brain injury requires further
investigation [42].
Conclusion
In summary, ultrasound examination is the primary diagnostic
tool for the evaluation of fetal growth. In the presence of risk factors
and clinical conditions that are associated with IUGR, a comprehen-
sive gray-scale ultrasound examination of fetal anatomy, biometry,
and amniotic ﬂuid characteristics is required. In the absence of
routine clinical indications, ultrasound screening of these high-
risk pregnancies should be performed at 16e18 weeks for dating
(if not otherwise established) and again at 30e36 weeks. If small
fetal size is documented, Doppler ultrasound of the umbilical and
middle cerebral arteries and invasive tests are of critical importance
to identify fetusesmost likely to beneﬁt from antenatal surveillance
and perinatal interventions.
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